Seeking Alpha

Lexicon Pharmaceuticals (LXRX) +12.5% premarket after revealing positive top-line results from a...

Lexicon Pharmaceuticals (LXRX) +12.5% premarket after revealing positive top-line results from a midstage study for telotristat etiprate, its investigational new drug to treat carcinoid syndrome. The drug currently has fast track status and orphan drug designation from the FDA, and orphan drug designation from European regulators.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector